Pharmacogenomic Analysis of Samples From Subjects in Study RN1004-0082

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

195 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-02-29

Study Completion Date

2008-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is to identify variations in subjects genetic makeup that segregate responders from non-responders in respect of response to Juvidex in the clinical trial RN1004-0082

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

NCT01280825

Patients Undergoing Routine Health Care Heart Diseases Inflammatory Bowel Diseases +5 more

RECRUITING

Genetic and Epigenetic Basis of Chronic Wounds

NCT03793062

Chronic Wounds

RECRUITING

Pharmacogenetic Testing for Medication Management.

NCT02559193

Medication Management

WITHDRAWN

Utility of PharmacoGenomics for Reducing Adverse Drug Effects

NCT02081872

Genetics of Drug Metabolism

UNKNOWN

Method of Genetic Analysis in Genodermatoses

NCT03873285

Genodermatosis Rare Genetic Disease With Cutaneous Expression

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Injury to the skin results in the physical disruption of the normal cellular architecture and triggers wound healing: a process involving inflammation, cell proliferation and migration, cell recruitment, angiogenesis and extracellular matrix deposition. Growth factors and cytokines released from inflammatory cells dictate the function of those cells present within the wound. There is a clinical need for treatments that accelerate healing, as current therapies in this field are largely based on empirical treatments and are often ineffective or inadequate.Juvidex contains as an active ingredient mannose-6-phosphate (M-6-P), a naturally occurring low molecular weight monosaccharide. The proposed mechanism of action for Juvidex is antagonistic and involves inhibiting the activation of TGF-β1 and TGF-β2. Juvidex is being developed by Renovo as a therapeutic agent administered to accelerate the healing of acute wounds.

Technological advances in genetics are providing scientists with the tools necessary to investigate the relationships between genetic variation and unmanipulated and drug-influenced wound healing outcomes such as the speed of healing. Determining the link between genetic variation and drug response (pharmacogenomics) is becoming an increasingly important part of drug development. For example, Iressa, which antagonises the tyrosine kinase activity of the epithelial growth factor receptor (EGFR) only works in people that have a specific variation (or polymorphism) in the DNA sequence of the EGFR gene. For Renovo, comparing the genetic make-up - (genotypes) - of subjects who respond well and those who respond poorly to a treatment, as well as those who naturally heal faster or whose wounds heal more slowly, may help to better define the most appropriate group of patients in which to target a given treatment. An additional benefit of exploring genotypes in well-defined patient populations will be to help to improve our understanding of the underlying biology of wound healing and provide new targets for drug discovery and development.

Pharmacogenomics may ultimately lead to improved treatment of wound healing by using more effective drugs and safer prescribing regimes. In order to realise these benefits we need to be able to collect samples for genotyping analysis from the associated clinical trial. Renovo wishes to examine the DNA sequence of patients enrolled into its clinical studies in order to examine the variation in patients capacity to heal wounds. This study will analyse samples from subjects participating in clinical study RN1004-0082, a double blind, placebo controlled trial to investigate the efficacy and safety of two concentrations of Juvidex in accelerating the healing of split thickness skin graft donor sites using different dosing regimes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Wound

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects aged 18-85 years who have given written informed consent.
* Subjects have given written informed consent to participate in the study RN1004-0082.